Textbook of Interventional Cardiovascular Pharmacology

Nicolas Kipshidze, Jawad Fareed, Patrick W. Serruys, Jeff Moses

• Publisher: CRC Press
• Year: 2007
• eBook ISBN:
  9781040160411
• Topic: Medicine
• Subtopic: Cardiology

While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological t

Table of contents

• Cover
• Half Title
• Title Page
• Copyright Page
• Table of Contents
• Contributors
• Foreword
• Foreword
• Preface
• Acknowledgments
• Frontmatter
• 1 An overview of hemostasis and thrombosis
• 2 Principles of antiplatelet therapy
• 3 Glycoprotein llb/Illa inhibitors
• 4 Adenosine diphosphate receptor inhibitors
• 5 Phosphodiesterase inhibitors: dipyridamole and cilostazol
• 6 Heparin, low molecular weight heparin
• 7 Direct thrombin inhibition in percutaneous coronary intervention
• 8 Clinical application of direct antithrombin inhibitors in acute coronary syndrome
• 9 Oral antithrombin drugs
• 10 Rationale for direct factor Xa inhibitors in acute coronary syndromes
• 11 Combined anticoagulant and antiplatelet therapy
• 12 Fibrinolytic therapy
• 13 Resistance to antiplatelet drugs
• 14 Lipid-lowering agents
• 15 Improving the diagnosis and management of high blood pressure in the cardiac patient
• 16 Homocysteine regulators
• 17 Role of systemic antirestenotic drugs and results of current clinical trials
• 18 Role of systemic antineoplasic drugs in the treatment of restenosis after percutaneous stent implantation
• 19 Antioxidants
• 20 Iron chelation: deferoxamine and beyond
• 21 Stent-mediated local drug delivery
• 22 The application of controlled drug delivery principles to the development of drug-eluting stents
• 23 Brachytherapy
• 24 Polymers and drug-eluting stents
• 25 Utilization of antiproliferative and antimigratory compounds for the prevention of restenosis
• 26 Anti-inflammatory drugs, sirolimus, and inhibition of target of rapamycin and its effect on vascular diseases
• 27 Anti-migratory drugs and mechanisms of action
• 28 Antioangiogenetic drugs—mechanisms of action
• 29 Vasculoprotective approach for restenosis
• 30 Vascular endothelial growth factor
• 31 Gene therapy: role in myocardial protection
• 32 Antisense approach
• 33 Principles of photodynamic treatment
• 34 Angiogenesis and myogenesis
• 35 Growth factor therapy
• 36 Cell transplantation for cardiovascular repair
• 37 Clinical trials in cellular therapy
• 38 The heart failure patient
• 39 The acute coronary syndrome patient
• 40 Cardiovascular interventional pharmacology in the diabetic patient
• 41 Atrial fibrillation during catheterization
• 42 Contrast-induced nephropathy after percutaneous coronary interventions
• 43 Erectile dysfunction
• 44 Peripheral arterial disease
• 45 Pharmacotherapy peri-percutaneous coronary intervention
• 46 Pharmacologic management of patients with CTO interventions
• 47 Newer pharmacologic approaches targeting receptors and genes
• 48 Carotid artery stenting
• 49 Anticoagulants in peripheral vascular interventions
• 50 Repair of AAAs
• 51 Interventions for structural heart disease
• 52 Pharmacologic use of ethanol for myocardial septal ablation
• Epilogue: Anticoagulant management of patients undergoing interventional procedures
• Appendix A
• Appendix B
• Index